Your comprehensive guide to Jögren (Pilocarpine 5mg) therapy
Pilocarpine Hydrochloride Tablets USP 5 mg
Pilocarpine is a parasympathomimetic drug that activates muscarinic receptors to stimulate natural secretions from salivary, lacrimal, and other exocrine glands.
Pilocarpine is a parasympathomimetic agent that enhances secretion from exocrine glands by activating muscarinic receptors, especially M3 receptors. It increases saliva and tear production while improving mucosal hydration.
Selective muscarinic agonist activity
Stimulates salivary, lacrimal, and mucosal secretions for symptomatic relief
Helps restore moisture levels in eyes and mouth through continuous stimulation
Dry Eye Study (Felberg S et al., Arq Bras Oftalmol 2022):
Significant improvement in NEI-VFQ-25 score, TBUT and Schirmer’s test
Salivary Flow Study (Depinoy T et al., Rheumatol Ther 2021):
Significant increase in SSF and USSF (p = 0.018, 0.027)
Dry Eye Pilot Study: Mean Schirmer improvement of 4.37 mm and TBUT of 3.03 seconds (p < 0.001)
Pilocarpine is recommended by EULAR and BSR as part of symptomatic management in Sjögren's Disease, providing evidence-based support for its clinical use.
5 mg four times a day Administer orally with adequate fluids
Titrate based on tolerance and response Consider morning-only initiation in sensitive patients
Regular assessment of symptom improvement Monitor for adverse effects
Mild parasympathomimetic effects (sweating, headache)
Gastrointestinal symptoms (nausea, diarrhea)
Usually dose-dependent and transient
No long-term serious AEs reported in trials
Well-established safety profile
Extensive post-marketing experience